| FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up | 09/05 12:35 | zacks.com |
| Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report? | 09/04 12:35 | zacks.com |
| Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine | 09/04 07:00 | globenewswire.com |
| Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. | 08/21 07:00 | globenewswire.com |
| Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth | 08/15 12:06 | zacks.com |
| AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm | 08/10 21:00 | globenewswire.com |
| Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade) | 08/06 15:45 | seekingalpha.com |
| Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates | 08/05 12:30 | zacks.com |
| Why Axsome Therapeutics Stock Is Sinking Today | 08/05 12:15 | fool.com |
| Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript | 08/05 11:20 | seekingalpha.com |